RIGL
Rigel Pharmaceuticals Inc
NASDAQ: RIGL · HEALTHCARE · BIOTECHNOLOGY
$29.37
-1.06% today
Updated 2026-06-05
Market cap
$593.55M
P/E ratio
1.66
P/S ratio
1.90x
EPS (TTM)
$19.29
Dividend yield
—
52W range
$18 – $52
Volume
0.4M
WallStSmart proprietary scores
65
out of 100
Grade: B
Buy
Investment rating
6.0
Growth
B6.5
Quality
B9.5
Profitability
A+8.3
Valuation
A5/9
Piotroski F-Score
Moderate
0.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$53.20
+81.14%
12-Month target
$32.39
+10.28%
Intrinsic (DCF)
$283.28
Margin of safety
+87.67%
0 Strong Buy3 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 121.50% — above average
+ ROE 91.08% — strong efficiency
+ Free cash flow $2.73M — positive
+ Revenue growth 10.30% QoQ
+ 87.67% below intrinsic value
Risks
- Altman Z 0.87 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $120.24M | $116.88M | $179.28M | $294.28M | $299.77M |
| Net income | $-58.57M | $-25.09M | $17.48M | $367.02M | $8.65M |
| EPS | — | — | — | — | $19.29 |
| Free cash flow | $-74.21M | $-20.74M | $31.07M | $75.66M | $2.73M |
| Profit margin | -48.71% | -21.47% | 9.75% | 124.72% | 121.50% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-01 | SCHORNO, DEAN L | Sale | 2,181 | — |
| 2026-06-01 | SCHORNO, DEAN L | Sale | 1,200 | — |
| 2026-06-01 | SCHORNO, DEAN L | Buy | 2,181 | $12.70 |
Peer comparison
Smart narrative
Rigel Pharmaceuticals Inc trades at $29.37. representing a P/E of 1.66x trailing earnings. Our Smart Value Score of 65/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 0.87, it sits in the distress. TTM revenue stands at $299.77M. with profit margins at 121.50%. Our DCF model estimates intrinsic value at $283.28.
Frequently asked questions
What is Rigel Pharmaceuticals Inc's stock price?
Rigel Pharmaceuticals Inc (RIGL) trades at $29.37, on a P/E of 1.7x and a P/S of 1.9x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Rigel Pharmaceuticals Inc overvalued?
Rigel Pharmaceuticals Inc carries a Smart Value Score of 65/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $283.28 versus the $29.37 price, a 87.7% margin of safety on a cash flow basis.
What is the price target of Rigel Pharmaceuticals Inc (RIGL)?
The 12-month analyst consensus target is $53.20, about 81.1% above the current $29.37. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of RIGL by 2030?
Our research-backed model puts the 2030 base case at $54.79, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Rigel Pharmaceuticals Inc (RIGL)?
Our DCF model estimates intrinsic value at $283.28, a +87.7% margin of safety versus today's $29.37. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Rigel Pharmaceuticals Inc's revenue?
Rigel Pharmaceuticals Inc's trailing twelve-month revenue is $299.77M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Rigel Pharmaceuticals Inc's Altman Z-Score is 0.87, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.90x
ROE91.08%
Beta1.18
50D MA$29.61
200D MA$34.27
Shares out0.02B
Float0.02B
Short ratio—
Avg volume0.4M
Performance
1 week+0.00%
1 month-6.85%
3 months+15.34%
YTD-30.12%
1 year—
3 years—
5 years—